Medicus Pharma Ltd., a biotech company based in the US, has received the FDA's acceptance of its Type C meeting request.
1 report, 1 independent
Updated Aug 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicus Pharma Ltd., a biotech company based in the US, has received the FDA's acceptance of its Type C meeting request.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Andrew Smith was appointed Chief Operating Officer of Medicus Pharma Ltd. on June 23, 2025.Sub-event
FDA accepted Type C meeting request from US-based biotech Medicus Pharma Ltd.1 source
Keep exploring
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- Cronus Pharma LLC, headquartered in East Brunswick, is launching products in the U.S. market and seeking FDA approval.
- A company is seeking FDA 510(k) clearance while simultaneously conducting a private placement and qualifying its prospectus in British Columbia.
- Providence Medical Technology, Inc. received 510(k) clearance from the FDA and plans to showcase its system at the Henry B. González Convention Center.
Coverage
Newest first; wire copies grouped- NewsfileMedicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Secon